Entegris Inc vs Revolution Medicines Inc. Common Stock — how do they compare? Entegris Inc trades at $163.41 (market cap $24.78B), while Revolution Medicines Inc. Common Stock trades at $190 (market cap $40.32B). The key difference: Revolution Medicines Inc. Common Stock is the larger of the two by market cap, and Entegris Inc pays a 0.25% dividend while Revolution Medicines Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Entegris Inc for 41 Days and Revolution Medicines Inc. Common Stock for 0 Days on average.
| ENTG | RVMD | |
|---|---|---|
Market Cap | $24.78B | $40.32B |
Volume | 2,648,320 | 4,855,734 |
Sector | Technology | Health |
52-Week High | $184.00 | $221.15 |
52-Week Low | $68.80 | $47.50 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | $27.99B | $37.02B |
Dividend Yield | 0.25% | — |
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $166.32, down 0.34% on the day, with a bullish technical signal and strong institutional backing. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.93 surpassing the $0.822 forecast. Revenue remains stable around $3.2B, while profitability metrics show a net income margin of 9.18%. Recent news highlights robust AI-driven semiconductor demand and successful patent defenses.
The outlook is positive, supported by analyst consensus with a $182.43 price target and 70% buy ratings. Key opportunities include exposure to growing semiconductor complexity and AI investments. Risks involve high valuation multiples, such as a P/E of 81.1, and sensitivity to semiconductor industry cycles.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →